Tsu‐Yi Chao

1.5k total citations
61 papers, 1.1k citations indexed

About

Tsu‐Yi Chao is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tsu‐Yi Chao has authored 61 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 15 papers in Surgery and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tsu‐Yi Chao's work include Lymphoma Diagnosis and Treatment (8 papers), Cancer Treatment and Pharmacology (7 papers) and Glioma Diagnosis and Treatment (5 papers). Tsu‐Yi Chao is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Cancer Treatment and Pharmacology (7 papers) and Glioma Diagnosis and Treatment (5 papers). Tsu‐Yi Chao collaborates with scholars based in Taiwan, United States and New Zealand. Tsu‐Yi Chao's co-authors include Ching‐Liang Ho, M.-S. Dai, Jang‐Jih Lu, Ann‐Lii Cheng, Chi‐Tai Yeh, Ming-Chih Chang, L.-T. Chen, Chao-Jung Tsao, Ih‐Jen Su and Chih‐Hung Hsu and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Cancer.

In The Last Decade

Tsu‐Yi Chao

59 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tsu‐Yi Chao Taiwan 18 375 337 309 217 212 61 1.1k
Frank S. Fan Taiwan 20 298 0.8× 358 1.1× 194 0.6× 366 1.7× 256 1.2× 84 1.4k
Hyun Ju Kim South Korea 16 191 0.5× 355 1.1× 201 0.7× 250 1.2× 299 1.4× 50 1.2k
Joel B. Levine United States 15 219 0.6× 290 0.9× 126 0.4× 249 1.1× 267 1.3× 31 1.1k
Maximilian Schöniger–Hekele Austria 19 542 1.4× 165 0.5× 831 2.7× 414 1.9× 146 0.7× 35 1.5k
Ik Joo Chung South Korea 19 178 0.5× 352 1.0× 401 1.3× 231 1.1× 416 2.0× 57 1.4k
Lie Dai China 21 251 0.7× 201 0.6× 109 0.4× 174 0.8× 393 1.9× 118 1.5k
Jae‐Jun Shim South Korea 22 463 1.2× 393 1.2× 316 1.0× 334 1.5× 127 0.6× 75 1.2k
Cem Şimşek Türkiye 18 343 0.9× 178 0.5× 268 0.9× 654 3.0× 165 0.8× 138 1.3k
Saiho Ko Japan 19 248 0.7× 215 0.6× 472 1.5× 561 2.6× 181 0.9× 68 1.3k
Alberto A. Diaz‐Arias United States 21 403 1.1× 324 1.0× 81 0.3× 448 2.1× 212 1.0× 55 1.4k

Countries citing papers authored by Tsu‐Yi Chao

Since Specialization
Citations

This map shows the geographic impact of Tsu‐Yi Chao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tsu‐Yi Chao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tsu‐Yi Chao more than expected).

Fields of papers citing papers by Tsu‐Yi Chao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tsu‐Yi Chao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tsu‐Yi Chao. The network helps show where Tsu‐Yi Chao may publish in the future.

Co-authorship network of co-authors of Tsu‐Yi Chao

This figure shows the co-authorship network connecting the top 25 collaborators of Tsu‐Yi Chao. A scholar is included among the top collaborators of Tsu‐Yi Chao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tsu‐Yi Chao. Tsu‐Yi Chao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Song, Dawei, et al.. (2025). S-hydroxychloroquine prevents the antiphospholipid thrombogenic complexes for antiphospholipid syndrome treatment. Biomedicine & Pharmacotherapy. 186. 117968–117968.
2.
Ho, Ching‐Liang, Tsu‐Yi Chao, Chia‐Lun Chang, & Hsuan-Yu Lin. (2024). Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study. BioDrugs. 38(2). 287–299. 2 indexed citations
3.
4.
Dai, Ming‐Shen, Ta‐Chung Chao, Ta‐Chung Chao, et al.. (2023). Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study. Therapeutic Advances in Medical Oncology. 15. 2628416–2628416. 2 indexed citations
5.
Wu, Yuan‐Hung, Heng‐Sheng Chao, Chi‐Lu Chiang, et al.. (2023). Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell‐derived organoids. Thoracic Cancer. 14(25). 2591–2600. 4 indexed citations
6.
Lee, Chia‐Hwa, et al.. (2023). Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma. European Journal of Pharmacology. 943. 175526–175526. 24 indexed citations
7.
8.
He, Zhijian, Christopher Jackson, Sanjeev Deva, et al.. (2022). Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors. CPT Pharmacometrics & Systems Pharmacology. 11(7). 867–879. 4 indexed citations
9.
Jackson, Christopher, Eva Segelov, Hans Prenen, et al.. (2021). Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study. British Journal of Clinical Pharmacology. 87(12). 4670–4680. 11 indexed citations
10.
Lee, Yi‐Ching, Chi‐Tai Yeh, Tsu‐Yi Chao, et al.. (2021). Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy. Theranostics. 11(8). 3624–3641. 17 indexed citations
11.
Chao, Tsu‐Yi, et al.. (2020). Dual therapeutic strategy targeting tumor cells and tumor microenvironment in triple-negative breast cancer. Journal of Cancer Research and Practice. 7(4). 139–139. 2 indexed citations
12.
Chen, Tom Wei‐Wu, Dah‐Cherng Yeh, Tsu‐Yi Chao, et al.. (2017). A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer. Japanese Journal of Clinical Oncology. 48(3). 242–247. 2 indexed citations
13.
Wu, Yi‐Ying, et al.. (2015). A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer. Oncology Letters. 10(3). 1793–1798. 1 indexed citations
14.
Yu, Jyh‐Cherng, Chi‐Hong Chu, Ching‐Liang Ho, et al.. (2014). Distinct MR Imaging Features of Triple‐Negative Breast Cancer with Brain Metastasis. Journal of Neuroimaging. 25(3). 474–481. 27 indexed citations
15.
Wu, Mei‐Yi, Tung‐Cheng Chang, Tsu‐Yi Chao, Ming‐Te Huang, & Hui‐Wen Lin. (2013). Risk of Colorectal Cancer in Chronic Kidney Disease: A Matched Cohort Study Based on Administrative Data. Annals of Surgical Oncology. 20(12). 3885–3891. 24 indexed citations
16.
Huang, Tzu‐Chuan, Ping‐Ying Chang, Ming–Shen Dai, et al.. (2013). Malignant bowel obstruction: A retrospective clinical analysis. Molecular and Clinical Oncology. 2(1). 13–18. 7 indexed citations
17.
Chao, Tsu‐Yi, et al.. (2009). Clinical Outcomes of Patients with Epidermal Growth Factor Receptor (Egfr ) Mutations (Mut) in Ipass (Iressatm Pan Asia Study). Journal of Thoracic Oncology. 4(1). 2 indexed citations
18.
Hsu, Chiun, Chiun‐Sheng Huang, Tsu‐Yi Chao, et al.. (2002). Phase II trial combining paclitaxel with 24‐hour infusion cisplatin for chemotherapy‐naïve patients with locally advanced or metastatic breast carcinoma. Cancer. 95(10). 2044–2050. 10 indexed citations
19.
Chen, Y., et al.. (2001). Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients. Annals of Hematology. 80(11). 647–652. 12 indexed citations
20.
Chao, Tsu‐Yi, et al.. (1995). Effects of Indomethacin on Lymphokine-Activated Killer Cell Activities in Cancer Patients. Tumor Biology. 16(4). 230–242. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frank S. Fan Breakdown of academic impact, for papers by Hyun Ju Kim Breakdown of academic impact, for papers by Joel B. Levine Breakdown of academic impact, for papers by Maximilian Schöniger–Hekele Breakdown of academic impact, for papers by Ik Joo Chung Breakdown of academic impact, for papers by Lie Dai Breakdown of academic impact, for papers by Jae‐Jun Shim Breakdown of academic impact, for papers by Cem Şimşek Breakdown of academic impact, for papers by Saiho Ko Breakdown of academic impact, for papers by Alberto A. Diaz‐Arias
Rankless by CCL
2026